WorldStage– Juli Plc has released its unaudited financial statements for the third quarter ended September 30, 2026, revealing sharp top-line contraction alongside aggressive operating cost reductions that narrowed its year-to-date net loss.
Top-Line Contraction Driven by Core Segments
For the three months ended September 30, 2026, Juli Plc recorded a 54.6% year-on-year drop in turnover to ₦51.64 million, down from ₦113.87 million in Q3 2025. The decline was driven primarily by weaker sales in its core pharmaceuticals division, which fell from ₦105.50 million to ₦46.77 million, alongside a contraction in household consumer goods revenue from ₦8.37 million to ₦4.87 million.
On a nine-month cumulative basis (January – September 2026), total revenue fell 48.2% to ₦198.50 million, compared to ₦383.11 million in the corresponding period of 2025.
Cost Containment Cushions Bottom-Line Impact
Despite lower gross profit—which stood at ₦15.49 million in Q3 2026 versus ₦39.28 million in Q3 2025—management curtailed administrative and operating expenses across the board:
Quarterly Operating Expenses: Total administrative expenses dropped 25.4% in Q3 2026 to ₦46.11 million (from ₦61.79 million in Q3 2025), aided by the absence of loan repayment charges and fines recorded in the prior-year period, as well as lower staff salaries and wages (₦6.76 million vs. ₦10.78 million). However, generator fuel and lubricant costs rose 37.4% to ₦9.74 million, and non-audit professional fees jumped to ₦18.54 million.
Nine-Month Loss Improvement: Over the nine-month period, total administrative expenses fell 40.7% to ₦107.89 million (down from ₦182.07 million in 9M 2025). As a result, Juli Plc narrowed its cumulative pre-tax loss by 18.6% to ₦43.67 million, improving on the ₦53.66 million loss posted in 9M 2025. In Q3 alone, the company posted a net loss of ₦30.62 million, compared to a loss of ₦22.51 million in Q3 2025.
Financial Summary
| Metric | Q3 2026 (3M) | Q3 2025 (3M) | YoY Change | 9M 2026 (YTD) | 9M 2025 (YTD) | YoY Change |
| Turnover | ₦51.64M | ₦113.87M | -54.6% | ₦198.50M | ₦383.11M | -48.2% |
| Cost of Sales | ₦36.15M | ₦74.59M | -51.5% | ₦134.28M | ₦254.71M | -47.3% |
| Gross Profit | ₦15.49M | ₦39.28M | -60.6% | ₦64.21M | ₦128.40M | -50.0% |
| Admin. Expenses | ₦46.11M | ₦61.79M | -25.4% | ₦107.89M | ₦182.07M | -40.7% |
| Net Loss | (₦30.62M) | (₦22.51M) | +36.0% | (₦43.67M) | (₦53.66M) | -18.6% |
Balance Sheet & Liquidity Snapshot
As of September 30, 2026, Juli Plc’s balance sheet reflects ongoing liquidity and solvency pressures:
Total Assets: Declined 36.4% from ₦218.04 million (FY 2025) to ₦138.62 million, largely due to inventory drawdowns (from ₦46.91 million to ₦25.02 million) and a reduction in goodwill/intangible carrying values (from ₦151.77 million to ₦107.06 million).
Liabilities & Debt: Total liabilities increased 22.5% to ₦186.61 million (up from ₦152.40 million at year-end 2025), driven by a restructured term loan with Wema Bank rising to ₦114.06 million and higher trade payables and accruals of ₦41.68 million.
Shareholders’ Equity: Accumulated retained losses widened to ₦885.23 million, leaving the company with a negative shareholders’ equity position of ₦47.99 million (compared to negative ₦26.80 million as of December 31, 2025).
Investor Takeaway
While Juli Plc demonstrated discipline in scaling back overhead and debt-servicing outflows over the nine-month stretch, the steep contraction in pharmaceutical revenues, rising energy costs, and negative equity position underscore the need for top-line recovery and balance sheet recapitalization going into the final quarter of 2026.





















































